PMID- 30157405
OWN - NLM
STAT- MEDLINE
DCOM- 20180914
LR  - 20180914
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 379
IP  - 9
DP  - 2018 Aug 30
TI  - Bile Acids, the Microbiome, Immunity, and Liver Tumors.
PG  - 888-890
LID - 10.1056/NEJMcibr1807106 [doi]
FAU - Schramm, Christoph
AU  - Schramm C
AD  - From the 1st Department of Medicine and Martin Zeitz Center for Rare Diseases,
      University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Bile Acids and Salts)
RN  - 0 (Receptors, CXCR6)
SB  - AIM
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/pharmacology
MH  - Bile Acids and Salts/*metabolism
MH  - Disease Models, Animal
MH  - Endothelial Cells/metabolism
MH  - Gastrointestinal Microbiome/drug effects/*immunology
MH  - Humans
MH  - Liver/*metabolism
MH  - Liver Neoplasms/*immunology
MH  - Mice
MH  - Natural Killer T-Cells/*immunology
MH  - Receptors, CXCR6/metabolism
EDAT- 2018/08/30 06:00
MHDA- 2018/09/15 06:00
CRDT- 2018/08/30 06:00
PHST- 2018/08/30 06:00 [entrez]
PHST- 2018/08/30 06:00 [pubmed]
PHST- 2018/09/15 06:00 [medline]
AID - 10.1056/NEJMcibr1807106 [doi]
PST - ppublish
SO  - N Engl J Med. 2018 Aug 30;379(9):888-890. doi: 10.1056/NEJMcibr1807106.